1. Fukuoka M, Yano S, Giaccone G, et al. Final results from a phase II trial of ZD1839 (‘Iressa’) for patients with advanced non-small-cell lung cancer (IDEAL 1) [Abstract]. Proc Am Soc Clin Oncol 2002; 21:298a
2. Kris MG, Natale RB, Herbst RS, et al. A phase II trial of ZD1839 (′Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2) [Abstract]. Proc Am Soc Clin Oncol 2002;21:292a
3. Phase II Trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck;Cohen;J Clin Oncol,2003
4. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145;Peng;Cancer Res,1996
5. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck;Huang;Cancer Res,1999